Novel brain-penetrant inhibitor of G9a methylase blocks Alzheimer's disease proteopathology for precision medication.
Res Sq
; 2023 Nov 21.
Article
in En
| MEDLINE
| ID: mdl-38045363
AD cognitive and noncognitive symptoms; AD diagnosis biomarkers; AD pathogenesis; blood-brain barrier (BBB); brain-penetrant inhibitor; companion diagnosis; mechanism of drug action; mechanism-based therapy; mouse-human conservation; noncanonical translational mechanism; proteomics; proteopathology; signaling pathways